Why PMV Pharmaceuticals, Inc.’s (PMVP) Stock Is Down 9.63%
As of Friday, October 30, PMV Pharmaceuticals, Inc.’s PMVP share price has dipped by 9.63%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Rosalio Madrigal
Jenna Brashear
Jenna Brashear
Jenna Brashear
| Share Statistics | PMVP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $95.9 | $211.8 | 22% |
|
| Shares Out (Mil) | 66.2 | 55.4 | 54% |
|
| Institutional Ownership | 94.2% | 93.0% | 64% |
|
| Float (Mil) | 59.1 | 41.5 | 50% |
|
| Beta | na | 0.99 | na |
|
| Avg Daily Volume (000s) | 367 | 553 | 53% |
|
| Price Change (52-week) |
(10.6%) | 42.8% | 42% |
|
| Growth | PMVP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (17.7%) | (10.3%) | 22% |
|
| EPS (5yr) | 9.2% | 15.8% | 46 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (14.9%) | (15.7%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 2 | 2 | |
| Current EPS | ($0.210) | ($1.225) | ($0.990) | |
| Month Ago EPS | ($0.293) | ($1.283) | ($0.967) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.333) | ($1.400) | ($1.077) | |
| Year/Year Chg | (59.6%) | (17.2%) | (34.5%) | |
| Financials | PMVP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $41 | na |
|
| Net Income (TTM) (Mil) | ($89) | ($44) | 12% |
|
| EPS (TTM) | ($1.565) | ($1.500) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($70) | ($35) | 8% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($10) | $147 | 2% |
|
| Valuation | PMVP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.67 | 2.01 | 48% |
|
| P/E | na | 17.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | PMVP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.9% | na |
|
| Net Margin | na | (50.6%) | na |
|
| ROA | (72.2%) | (47.4%) | 8% |
|
| ROE | (99.4%) | (53.1%) | 9% |
|
| Liabilities to Assets | 48.7% | 29.7% | 41% |
|
| F-Score | 2 | 3 | 7% |
|
PMV Pharmaceuticals, Inc. did not pass any screens on 11/13/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors